NanoEcho
0.07 SEK
-5.28 %
Less than 1K followers
NANECH
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-5.28 %
-6.73 %
+21.69 %
-18.15 %
-8.13 %
-59.62 %
-
-
-52.86 %
NanoEcho operates in the healthcare sector, with a primary focus on rectal cancer diagnostics. The company is currently in the clinical stage, developing a new diagnostic method to determine whether early rectal cancer has spread to nearby lymph nodes. The method aims to provide an accurate diagnosis and personalized treatment. NanoEcho was founded in 2013 and is headquartered in Lund.
Read moreMarket cap
21.53M SEK
Turnover
16.27K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
12/2
2026
Annual report '25
30/4
2026
Interim report Q1'26
28/5
2026
General meeting '26
All
Press releases
3rd party
ShowingAll content types
NanoEcho publicerar investerarbrev
NanoEcho har genomfört förbättringar av algoritmen inför inledande del av Proof of Concept-studien
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools